T-cell large granular lymphocytic (T LGL) leukemia is a rare, usually slow-growing blood disorder in which a single clone of cytotoxic T cells expands and persists in the blood, bone marrow and spleen. Its pathophysiology centers on chronic immune stimulation and faulty cell-death signaling, often driven by STAT3 mutations. Diagnosis relies on a blood count, flow cytometry and a test showing the T cells are clonal, and treatment is only needed when the disorder causes problems such as severe neutropenia or anemia, most often with low-dose immunosuppressive drugs such as methotrexate.
Many people with T LGL leukemia live for years with little or no treatment. In my practice, the first conversation is often about the word “leukemia” itself, because this condition behaves very differently from acute leukemias. Our overview of LGL leukemia diagnostics and management covers the wider LGL family, including the NK-cell types.
What Is T LGL Leukemia?
Large granular lymphocytes are a normal part of the immune system. They are bigger than ordinary lymphocytes and carry granules filled with proteins such as perforin and granzymes, which they use to kill infected or abnormal cells. Most are either cytotoxic CD8+ T cells or natural killer (NK) cells.
In T LGL leukemia, one T-cell clone keeps expanding instead of dying off once its job is done. The condition is classed as a chronic lymphoproliferative disorder. It usually appears in middle-aged and older adults and affects men and women roughly equally.
Pathophysiology: Why the Cells Accumulate
The disorder is best understood as an immune response that never switches off. Three processes work together.
Chronic antigen stimulation
The leading theory is that an ongoing trigger, possibly a viral antigen or a self-antigen in an autoimmune disease, repeatedly activates a group of T cells. Over time, one clone gains a survival advantage and dominates.
Failure of programmed cell death
Normally, activated T cells are removed through apoptosis once an immune response ends. In T LGL leukemia, survival pathways stay switched on and the Fas/Fas-ligand death pathway does not work properly, so the cells live far longer than they should.
STAT3 and STAT5B mutations
A substantial proportion of patients have activating mutations in the STAT3 gene, and a smaller number have STAT5B mutations. These genes relay signals from cytokines into the cell nucleus. When mutated, they keep survival signaling permanently active. STAT3 mutations are particularly associated with neutropenia and autoimmune features.
How the clone causes low blood counts
The expanded T cells release cytokines and death signals, such as soluble Fas-ligand, that destroy neutrophils and suppress their production. They can also attack red cell precursors, causing pure red cell aplasia. Infiltration of the bone marrow and spleen adds to the problem.
Symptoms and Associated Conditions
Many patients have no symptoms when diagnosed, and the disorder is picked up on routine bloodwork. When symptoms occur, they usually reflect low blood counts.
- Recurrent infections, such as skin infections, mouth ulcers, pneumonia or sinus infections, from neutropenia
- Fatigue and breathlessness from anemia
- Easy bruising or bleeding when platelets are low, which is less common
- An enlarged spleen, which may cause abdominal fullness
- Fevers, night sweats or weight loss in a minority of patients
T LGL leukemia is strongly linked with autoimmune disease, especially rheumatoid arthritis. The combination of rheumatoid arthritis, neutropenia and an enlarged spleen is known as Felty syndrome, which overlaps closely with T LGL leukemia.
How T LGL Leukemia Is Diagnosed
Diagnosis combines three types of evidence: an increased number of LGLs, a typical immune marker pattern, and proof that the cells come from one clone.
| Test | What it shows | Typical finding in T LGL leukemia |
|---|---|---|
| Complete blood count and blood film | Cell counts and cell appearance | Neutropenia and/or anemia; increased large lymphocytes with granules |
| Flow cytometry | Surface markers on the lymphocytes | CD3+, CD8+, CD57+, often CD16+, usually CD56- |
| T-cell receptor gene rearrangement | Whether cells are clonal | A single dominant clone |
| STAT3 / STAT5B mutation testing | Driver mutations | Positive in many patients; supports the diagnosis |
| Bone marrow biopsy | Marrow infiltration and other causes | Clusters of cytotoxic T cells; excludes other disorders |
A sustained LGL count above about 2,000 cells per microliter has traditionally been used as a threshold, but the diagnosis can be made at lower counts when clonality is proven and the clinical picture fits. The expansion should persist for several months, because temporary increases in LGLs are common after viral infections and transplants.
Conditions to rule out
Doctors distinguish T LGL leukemia from reactive LGL expansions, other T-cell lymphomas, chronic NK-cell lymphocytosis and the aggressive NK-cell leukemia. Other causes of neutropenia, such as drug reactions, are also considered.
Treatment and Management
Not everyone needs treatment. Many patients are monitored with regular blood counts, a strategy often called watch and wait.
When treatment is recommended
- Severe neutropenia, particularly an absolute neutrophil count below 500 cells per microliter
- Moderate neutropenia with recurrent infections
- Symptomatic or transfusion-dependent anemia
- An associated autoimmune condition that needs therapy
First-line options
Treatment aims to suppress the abnormal clone rather than eliminate it. The three standard first-line drugs are:
- Low-dose methotrexate, taken weekly by mouth, often preferred for neutropenia and in patients with rheumatoid arthritis
- Oral cyclophosphamide, often favored for anemia and pure red cell aplasia, usually for a limited period
- Cyclosporine, an immunosuppressant used first line or after other options
These drugs take several months to show their full effect. Corticosteroids may be used briefly alongside them but do not control the disease on their own. G-CSF can help raise neutrophils during infections.
Refractory disease
If first-line drugs fail, specialists may switch to another first-line agent or consider options such as purine analogues, alemtuzumab or, in selected cases, splenectomy. Targeted drugs that block the JAK-STAT pathway are being studied in clinical trials.
Outlook and Long-Term Monitoring
T LGL leukemia is usually chronic and indolent, and most patients have a long survival. The main risks come from infections related to neutropenia. Regular blood counts, prompt attention to fevers, and monitoring for drug side effects such as liver or kidney changes are the backbone of long-term care. For related topics, see our leukemia guide.
When to See a Doctor
See your doctor if you have repeated infections, mouth ulcers, unexplained fatigue or a blood test showing persistent neutropenia or raised lymphocytes. If you already have T LGL leukemia with neutropenia, a fever of 38°C (100.4°F) or higher needs urgent medical attention the same day.
Frequently Asked Questions
Is T LGL leukemia a cancer?
It is classified as a mature T-cell neoplasm, so technically it is a blood cancer. However, it usually behaves more like a chronic immune disorder than an aggressive cancer, and many people never need chemotherapy in the usual sense.
Can T LGL leukemia be cured?
Current treatments control the disease rather than cure it. Many patients achieve normal or near-normal blood counts on treatment and can stop therapy for periods, restarting if counts fall again.
Why is T LGL leukemia linked to rheumatoid arthritis?
Both conditions involve chronic immune activation, and the same persistent stimulation may drive the expansion of a T-cell clone. This overlap explains why methotrexate, a standard rheumatoid arthritis drug, is also a first-line treatment for T LGL leukemia.
Does T LGL leukemia turn into acute leukemia?
Transformation into an aggressive leukemia is very rare. Most problems come from low blood counts rather than disease progression.
Key Takeaways
- T LGL leukemia is a chronic clonal expansion of cytotoxic CD8+ T cells.
- Chronic immune stimulation, failed apoptosis and STAT3 mutations drive the disease.
- Neutropenia, anemia and autoimmune disease, especially rheumatoid arthritis, are common.
- Diagnosis needs flow cytometry and proof of clonality, supported by mutation testing.
- Treatment is reserved for significant cytopenias or symptoms, using methotrexate, cyclophosphamide or cyclosporine.
